Indexado en

Enlace externo

Licencia y uso

Citaciones

Altmetrics

Análisis de autorías institucional

Loscertales, JavierAutor o Coautor

Compartir

Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC)

Publicado en:LEUKEMIA & LYMPHOMA. 55 (5): 1007-1012 - 2014-05-01 55(5), DOI: 10.3109/10428194.2013.827187

Autores: Lopez Rubio, Montserrat; Da Silva, Carolina; Loscertales, Javier; Seri, Cristina; Baltasar, Patricia; Colado, Enrique; Perez Fernandez, Inmaculada; Osma, Mar; Gomis, Federico; Gonzalez, Marcos; Jarque, Isidro; Vargas, Manuel; Monzo, Encarnacion; Monteagudo, Dolores; Isabel Orts, Maria; Pardal, Emilia; Carbonell, Felix; Perez Calvo, Cesar; Garcia-Marco, Jose A

Afiliaciones

Resumen

Purine analogs are highly effective in hairy cell leukemia (HCL) with response rates of 85%, but with many late relapses. We have retrospectively reviewed the clinical data from 107 patients treated with pentostatin (n = 27) or cladribine (n = 80), to investigate the long-term efficacy and to identify factors associated with the treatment-free interval (TFI). Complete remission and minimal residual disease (MRD) rates were similar in both groups. Median TFI was shorter (95 vs. 144 months) in the pentostatin group, although the difference was not significant (p = 0.476). MRD+ patients had shorter TFI than MRD - patients (97 months vs. not reached, p < 0.049). A hemoglobin level < 10 g/dL predicted for a shorter TFI only in the pentostatin group. Quality of response and number of hairy cells in the bone marrow are independent risk factors of treatment failure. The relationship between MRD+ and shorter TFI makes it of special interest to explore consolidation therapy with monoclonal antibodies to achieve durable responses.

Palabras clave